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Background and Aims: Non-specific gastric inflammation (NSGI) is a commonly reported
pathological finding. We investigated if it is associated with the use of proton pump
inhibitors (PPIs) in children at a single tertiary center.
Methods: We performed an IRB-approved chart review of all endoscopy and biopsy
reports of patients who underwent esophagogastroduodenoscopy between July 2009
and July 2010 (n=310). Demographic data, dose, duration of exposure to PPI, and biopsy
results were collected and analyzed. All esophageal, gastric, and duodenal biopsies were
independently reviewed by a pathologist. Patients with acute gastritis, moderate/severe
chronic gastric inflammation, or Helicobacter pylori infection were excluded. The pres-
ence of NSGI was compared between patients exposed and not exposed to PPI as well as
between patients with different doses and durations of PPI exposure to assess for potential
associations.
Results: A total of 193 patients were included: 88 (46%) had a history of PPI use and
48 (25%) were found to have NSGI. Compared to patients not exposed to PPI, the odds
ratio of NSGI in patients exposed to PPIs was 2.81 (95% CI: 1.36–5.93). The odds ratio of
NSGI in patients exposed to PPI for >3 months was 4.53 (95% CI: 1.69–11.97). Gender,
ethnicity, and age were not associated with NSGI. No histological differences were found
in the esophagus and duodenum between patients exposed and not exposed to PPI.
Conclusion:This study found that PPI exposure is associated with NSGI with a higher risk
for those exposed for >3 months. As the clinical implications of NSGI are not known, judi-
cious use of PPIs is needed. Prospective studies are required to confirm and to determine
the etiologic factors (i.e., alteration of the gastric pH, serum gastrin) that may be related
with the presence of NGSI.
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INTRODUCTION
Although proton pump inhibitors (PPIs) have shown a remark-
able tolerability profile, the clinical use of these agents in children
is based on adult data (1). In recent years, several studies have
shown that PPIs are associated with an increased risk of infectious
complications (pneumonia, Clostridium difficile infection, small
bowel bacterial overgrowth) and nutritional deficiencies (vitamin
B12 deficiency, osteoporosis) (2–4). Also, elevation of the gastric
pH related to PPI usage may have deleterious effects on the gas-
trointestinal tract, including delayed gastric emptying, increased
intestinal bacterial translocation, decreased gastric mucus viscos-
ity, changes in the normal microbial flora, and possible impaired
neutrophil function in vitro (5). Despite their safety profile, there
are concerns regarding the long-term use of these agents (3, 6, 7).
Elevated serum gastrin level is a reproducible finding in patients
taking PPIs, but its true clinical significance is yet unknown (2, 5,
8). As gastrin is a potent trophic hormone in the stomach (6),
hypergastrinemia has been associated with changes in gastric his-
tology in patients after long-term PPI use. These changes include
gastric polyps, gastric nodules, and parietal cell hyperplasia (8–10).
Several studies have reported non-specific gastric inflammation
(NSGI) as one of the most common histological findings (11, 12)
independent of PPI use. NSGI is characterized by mild chronic
inflammation with focal collections of lymphocytes and plasma
cells in the lamina propria predominantly in the antrum, and for
which there is no identified cause (12). Mild chronic inflamma-
tion was defined according to the Sydney classification for gastritis
(13, 14). The presence of tissue eosinophilia with peak eosinophil
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count was also recorded for all biopsies. The diagnosis of NSGI
was given to those biopsies with focal collections of lymphocytes
and plasma cells in the lamina propria.
In our practice, there has been a noticeable increase in the
number of patients with this pathologic finding in recent years.
The primary aim of this study was to determine if NSGI is
associated with PPI exposure. The secondary aims included the
description of morphological changes in the esophagus and the
duodenum (i.e., eosinophilic infiltration, peak eosinophil count),
as well as to determine if there is an association between PPI
duration, dose, and these changes.
MATERIALS AND METHODS
After obtaining approval from the Institutional Review Board, at
the University of Texas Health Science Center, we performed a
retrospective review of the medical records of all children who
underwent esophagogastroduodenoscopy (EGD) from July 2009
to July 2010 at Children’s Memorial Hermann Hospital (a uni-
versity affiliated hospital). The following demographic data was
ascertained from the medical records: age, sex, ethnicity, and
BMI. Endoscopy reports, procedure indication, and the associ-
ated pathology reports were reviewed. Dose, duration, and type
of PPI used prior to endoscopy were obtained. Patients up to
18 years of age, who had a normal EGD and had gastrointestinal
biopsies taken were included. Patients with history of Helicobacter
pylori infection, peptic ulcer disease, celiac disease, eosinophilic
gastroenteritis, reflux esophagitis, eosinophilic esophagitis, acute
gastritis, or moderate/severe chronic inflammation of the stomach
were excluded.
Subjects were divided in two groups for analysis: one group
with patients who had PPI exposure and the other group with
patients with no exposure to PPI prior to the EGD. Subjects with
inconsistent PPI use were included if their PPI exposure was for at
least six consecutive weeks prior to the endoscopy.
HISTOLOGICAL ANALYSIS
All biopsies were reviewed by a single pathologist who was blinded
to the patient’s clinical information. Esophageal, gastric, and duo-
denal biopsies were evaluated for adequacy of the submitted tissue,
architectural changes, inflammation, peak eosinophil count, and
presence of H. pylori. The presence of tissue eosinophilia with peak
eosinophil count was also recorded for all biopsies.
STATISTICAL ANALYSIS
Descriptive statistics was used for demographics, endoscopy indi-
cations, PPI usage pattern, and biopsy results. Odds ratios and
95% confidence intervals were calculated to evaluate any differ-
ence in odds of PPI use among individuals with and without
gastric inflammation. Stratified analysis and multivariable logis-
tic regression models were used to adjust PPI type, duration
(≤1.5, 1.5, 1.5–3.0, and >3 months), dosage (≤0.5, 0.5–1.0, and
>1.0 mg/kg/day), gender, ethnicity, age, and obesity. Statistical sig-
nificance was assumed at p< 0.05 or a confidence interval that did
not include the null.
RESULTS
After the initial review of 310 charts, 117 subjects were excluded
(reasons for their exclusion are listed in Table 1) and 193 children
Table 1 | Patients excluded from the analysis.
Initial review
H. pylori gastritis 28
Eosinophilic esophagitis 17




No gastric biopsies 6
Other 23b
After histological analysis





H. pylori gastritis 1
aCrohn’s disease (7), ulcerative colitis (3).
bOther: lupus, history of liver transplant, vasculitis, esophageal ulcers, short bowel
syndrome, pancreatitis, Candida esophagitis, lymphoma, achalasia, renal failure,
esophageal strictures, and immunodeficiency.
FIGURE 1 | Patient inclusion and exclusion algorithm. Flow chart of the
inclusion/exclusion criteria. PPI, proton pump inhibitors.
were included; 88 (45.6%) had PPI exposure prior to EGD
(Figure 1). There were no significant differences between PPI-
exposed and non-exposed on the basis of gender, age, ethnicity,
and BMI (Table 2).
PPI THERAPY
Lansoprazole was used by 61 subjects (69.3%), esomeprazole by 11
subjects (12.4%), other PPIs (omeprazole, rabeprazole, or panto-
prazole) by 9 subjects (10.2%). More than one type of PPI was used
by five (5.7%) subjects during the treatment course. The median
daily PPI dose was 0.89 mg/kg (IQR 0.53–1.20 mg/kg). Among
the patients with PPI exposure, 24 subjects (27.3%) received PPI
for <1 month, 14 subjects (15.9%) between 1 and 2 months, 38
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Table 2 | Patient demographics.
PPI use No PPI use p-Value
Total, n (%) 88 (45.6) 105 (54.4)
<6 weeks 33 (37.5)
>6 weeks 43 (48.9)
Intermittent 12 (13.6)
Gender, n (%)
Female 41 (21.2) 55 (28.5) p=0.423
Male 47 (24.4) 50 (25.9)
Age, mean (std. dev.) 9.35 (5.09) 8.27 (5.63) p=0.171
Ethnicity, n (%)a
White 46 (52.3) 41 (39.4) p=0.216
Hispanic 23 (26.1) 40 (38.5)
African American 12 (13.6) 12 (11.5)
Other 7 (8.0) 11 (10.6)
BMI, median (range)b 19.11 (13.1–32.17) 18.15 (12.69–41.8) p=0.456
Z score, median
(IQR)
0.46 (−3.2–4.65) 0.13 (−4.27–3.67) p=0.231
aData missing for one subject with no history of PPI use.
bData missing for 6 subjects with history of PPI use and 13 subjects with no
history.
subjects (43.2%) for >2 months, and 12 subjects (13.6%) used
PPI inconsistently for at least 6 weeks.
HISTOLOGICAL FINDINGS
The biopsies of 193 patients were reviewed: 48 (24.8%) had NSGI
(Figure 2); 7 (3.6%) subjects had NSGI with isolated lymphoid
aggregate (ILA); 8 (4.1%) had NSGI with lymphoid follicle (LF)
in the same biopsy specimen. Other gastric findings included: 27
patients (13.9%) had LFs and germinal centers in the absence of
H. pylori infection; 11 (5.7%) had ILAs, represented by a lymphoid
conglomerate without germinal center; and 3 (1.6%) had foveolar
hyperplasia. The remaining 145 subjects (76%) had normal gas-
tric histology. Gender, ethnicity, age, and BMI were not associated
with NSGI in multivariable models.
Other histological findings included: 20 patients (10.4%) with
mild duodenal chronic inflammation and 24 (12.4%) with a mild
esophageal lymphocytic infiltrate.
STOMACH INFLAMMATION AND PPI USE
Among the patients with NSGI, 31/48 (64.6%) had PPI exposure
and when compared to patients not exposed to PPI, their odds
ratio of having NSGI was 2.81 (95% CI: 1.36–5.93). The odds
ratio of NSGI for patients exposed to lansoprazole was 2.04 (95%
CI 1.04–4.02) (the OR for patients exposed to other PPIs did not
reach statistical significance).
In order to assess the association between duration of expo-
sure to PPI and NSGI, PPI-exposed patients were stratified in
two groups: <6 weeks of treatment and ≥6 weeks of treatment
(Table 3). Patients with NSGI were four times more likely to have
PPI exposure for >6 weeks when compared to patients without
NSGI (OR 4.10, 95% CI 1.85–9.07). The odds were not increased
if PPI exposure was briefer than 6 weeks. This higher risk of NSGI
with increasing duration of PPI exposure was also found after
FIGURE 2 | Gastric biopsies with non-specific gastric inflammation.
Gastric antral-type mucosa at low power with lymphoplasmacytic
inflammation expanding the lamina propria. The general architecture is
preserved with no erosions or acute inflammation.







No PPI use 17 88 –
PPI use 31 57 2.82 1.42–5.55
Duration <6 weeks 8 25 1.66 0.64–4.29
Dose 0.8–1 mg/kg/day 3 8 1.94 0.47–8.07
Dose >1 mg/kg/day 2 11 0.94 0.19–4.63
Duration ≥6 weeks 19 24 4.10 1.85–9.07
Dose 0.8–1 mg/kg/day 12 13 4.78 1.86–12.24
Dose >1 mg/kg/day 3 10 1.55 0.39–6.24
aNumbers in subgroups do not add up to sums in parent groups due to missing
data for duration (n=12) and dose (n=23).
bAll comparisons are to the non-PPI users.
further stratification into two additional groups: PPI exposure
between 6 weeks and 3 months (OR 3.24, 95% CI 0.97–11.09)
and PPI exposure for more than 3 months (OR 4.53, 95% CI
1.87–10.98).
Also aimed to assess the association between dose of PPI and
NSGI, patients exposed to PPI were compared to patients non-
exposed to PPI by using two different PPI doses at the time of
endoscopy. There was a statistically significant increased risk of
NSGI with the standard PPI dose (0.8–1 mg/kg; n= 38) (OR 3.77,
95% CI 1.65–8.61); however, the risk was not statistically sig-
nificant for higher doses (>1 mg/kg; n= 27) (OR 1.18, 95% CI
0.39–3.54) (Table 3). Additionally, a comparison of point esti-
mates between PPI exposed patients with >6 weeks duration of
treatment and those with<6 weeks duration,demonstrated higher
odds ratios for each dose range among patients exposed to PPI for
>6 weeks.
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Although age and gender were not independently associated
with either NSGI or PPI use, it was noted that the proportion of
younger subjects (<13 years-preteen) was mostly of female gender
(79.2% female vs. 60.8% male; p= 0.005). Gender appeared to be
associated with PPI-associated NSGI, as females with NSGI had a
greater than fivefold increased odds of having been exposed to PPI
(OR 5.78, 95% CI 2.02–16.55) compared to females without NSGI;
this association was not found in males (OR 1.50, 95% CI 0.60–
3.76). After adjusting for age (preteen vs. teenage) this increased
risk persisted for teenage females with a wide confidence interval
given the size of this group of patients. It was also noted that age did
not significantly influence the association between PPI exposure
and NSGI in males.
DUODENAL AND ESOPHAGEAL INFLAMMATION AND PPI USE
Among patients with mild chronic duodenal inflammation, com-
pared with children without inflammation, the odds of PPI expo-
sure were not significantly increased (OR 2.42, 95% CI 0.92–6.38).
However, an increased risk of mild chronic duodenal inflamma-
tion was found with a PPI exposure of >6 weeks (OR 3.2, 95%
CI 1.08–9.47) compared to children without inflammation. This
risk was not increased for PPI exposure of <6 weeks (OR 0.90,
95% CI 0.18–4.58). No increased risk of mild chronic duodenal
inflammation with different PPI doses in both groups was found.
There was no association between PPI exposure, dose or duration
of treatment, and esophageal lymphocytic inflammation.
EOSINOPHIL COUNT AND PPI USE
The peak eosinophil count per single high power field (eos/hpf)
was almost identical between those exposed and non-exposed to
PPI. Patients with NSGI had a median count of 3.5 eos/hpf (range
1–12 eos/hpf), and those without NSGI had a median count of
2 eos/hpf (range 1–11 eos/hpf). Duration or dose of PPI treatment
was not associated with changes in eosinophil count.
DISCUSSION
Our study shows an association between NSGI and long term
exposure to PPIs. Patients who were exposed to PPI for more than
6 weeks had a nearly fourfold increased risk of NSGI. This associ-
ation was even stronger in those who had PPI exposure for more
than 3 months. In a separate analysis of the different types of PPI
used, lansoprazole (66%), the most common PPI in this cohort
had the highest risk. Additional studies need to be conducted to
determine if specific PPIs are associated with a higher risk of NSGI.
The diagnosis of NSGI has been reported in prior retrospec-
tive studies. Pashankar et al. (11) reported that up to 57% of their
cohort had a diagnosis of NSGI, but they did not mention if the
patients had exposure to PPI. Tolia et al. (6) reported that NSGI
was one of the most frequently observed histological findings in
a pediatric cohort, being present in 15–38% of gastric biopsies.
These patients were exposed to PPIs for at least 1 year (different
PPIs had different risk of NSGI). In our study, NSGI was present
in 24% of all gastric biopsies reviewed, and it was seen in 33% of
patients who had been exposed to PPI before endoscopy. In addi-
tion, NSGI was seen in those patients who had been exposed to
PPI for at least 6 weeks, providing a more specific and narrow time
frame during which NSGI could develop. This change persisted
as long as the PPI therapy was continued. Future studies will be
needed to determine if NSGI resolves after PPI discontinuation
and the length of time this would take.
Our study also showed that higher doses of PPI (>1 mg/kg) may
not increase the risk of NSGI compared to the standard dose, but
the likely explanation is because there were more patients receiving
the standard dose (median PPI dose was 0.89 mg/kg/day in about
half of our cohort). Another reason for this finding might be that
clinicians were more attentive to patients receiving higher doses of
PPI and may have limited the duration of treatment.
Favorable effectiveness and safety profiles have led to a signif-
icant increase in prescription of PPIs in the last decade (14–16).
The “PPI trial” or short PPI use for 4–8 weeks is a common prac-
tice among clinicians as a diagnostic tool for gastroesophageal
reflux disease (GERD) (17, 18) and to rule in “PPI-responsive
eosinophilic esophagitis” (recent ACG guidelines). Many primary
care practitioners and gastroenterologists continue PPI therapy
for prolonged periods of time with no clear criteria for discontin-
uation (7, 19). Some patients could be receiving PPI therapy with
no clear medical indication, perhaps as a placebo, or as means
to maintain partial resolution of gastrointestinal symptoms. This
practice was evident in our study as 43% of patients on PPI under-
went an EGD for persistent symptoms despite the use of a PPI for
more than 2 months. To our knowledge, there have been no studies
exploring the role of prolonged acid suppression in patients who
have partial resolution of symptoms (i.e.,nausea, abdominal pain).
Although the clinical significance of NSGI has yet to be estab-
lished, the results of this study support using these therapeutic
agents for only the recommended trial period and at the standard
dose. If patients fail the recommended therapeutic trial, practi-
tioners should discontinue the medication and investigate other
potential causes.
The authors of this study believe that because several studies
have reported NSGI in children (a vulnerable population), inves-
tigations to understand the pathophysiology of NSGI are needed.
For example, PPIs may be handled differently by different patients
depending upon genetic differences. It is known that PPIs are
metabolized by the hepatocyte CYP2C19 and CYP3A4 enzymes
(1). Kearns et al. reported different genetic polymorphisms of
CYP2C19 that can lead to differences in PPI pharmacokinetics
(20). For instance, a patient with a poor metabolizer phenotype
for CYP2C19 has a higher plasma concentration from a therapeu-
tic dose of a PPI, which potentially could cause a more profound
acid suppression, perhaps increasing the risk for NSGI.
In addition to the increased risk of NSGI in children receiving
PPIs, gastric acid suppression can potentially interfere with the
natural antibacterial protection of gastric acid (5, 21–23) as well
as with the natural pH-dependent deactivation of refluxed pancre-
atic enzymes (24). The effect of prolonged gastric alkalinization
on the risk of systemic and gastrointestinal infection also needs
to be investigated. There have been many reports in adults and
children of fundic gastric polyps and/or cysts associated to PPI
use (5, 8). None of the EGD reports reviewed during this study
reported these lesions, even in patients exposed to PPI for more
than a year.
Although we acknowledge that the retrospective design of this
study is its main limitation, we also recognize that its sample
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size is one of its strengths. Some of the other limitations of
our study include the assumption that patients were taking the
medication at the dose and for the duration as documented in
their chart, and the assumption that gastric inflammation was not
present before the patient was exposed to PPI. A prospective pedi-
atric study to determine if PPI use increases the risk for NSGI
would be unethical as patients would be required to have multi-
ple endoscopies performed at different durations during their PPI
treatment.
In conclusion, PPI exposure for more than 6 weeks was associ-
ated with NSGI, with the highest risk among patients using higher
doses for longer periods of time. Although our study does not
establish causality, in patients with persistent symptoms despite
acid suppression, we question the benefit of continuing PPI ther-
apy beyond this time. We hypothesize that the NSGI is related
to a disruption in the normal gastric pH caused by PPIs use in
genetically susceptible individuals. Future prospective studies are
required for the understanding of the pathophysiology and natural
history of these changes in the gastric mucosa.
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